0001209191-22-001634.txt : 20220105
0001209191-22-001634.hdr.sgml : 20220105
20220105160807
ACCESSION NUMBER: 0001209191-22-001634
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20220103
FILED AS OF DATE: 20220105
DATE AS OF CHANGE: 20220105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Meyenburg Jason Patrick
CENTRAL INDEX KEY: 0001709008
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39438
FILM NUMBER: 22511188
MAIL ADDRESS:
STREET 1: C/O SUCAMPO PHARMACEUTICALS
STREET 2: 805 KING FARM BOULEVARD, SUITE 550
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Gemini Therapeutics, Inc. /DE
CENTRAL INDEX KEY: 0001816736
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851613057
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 ONE KENDALL SQUARE, 3RD FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: (617) 401-4400
MAIL ADDRESS:
STREET 1: 300 ONE KENDALL SQUARE, 3RD FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: FS Development Corp.
DATE OF NAME CHANGE: 20200702
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-03
0
0001816736
Gemini Therapeutics, Inc. /DE
GMTX
0001709008
Meyenburg Jason Patrick
C/O GEMINI THERAPEUTICS, INC.
NOT APPLICABLE
DE
1
1
0
0
Chief Executive Officer
Restricted Stock Units
2022-01-03
4
A
0
123600
0.00
A
Common Stock
123600
123600
D
Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock.
These Restricted Stock Units shall vest in accordance with certain performance based metrics.
/s/ Brian Piekos, attorney-in-fact
2022-01-05
EX-24
2
poa.txt
POA DOCUMENT
Exhibit 24
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and
appoints each of Brian Piekos, Nina Thayer, and Benjamin Marsh,
signing singly, the undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director of Gemini Therapeutics, Inc.
(the "Company"), (i) Form ID, including any attached documents, to
effect the assignment of codes to the undersigned to be used in the
transmission of information to the United States Securities and
Exchange Commission using the EDGAR System, (ii) Forms 3, 4 and 5,
(iii) Schedule 13D, (iv) Schedule 13G and (v) amendments of each
thereof, in accordance with Section 16(a) of the Securities
Exchange Act of 1934, as amended, and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and
execute any such Form 3, 4 or 5, Schedule 13D. Schedule 13G or any
amendments thereto and timely file such form with the United States
Securities and Exchange Commission and any stock exchange or
similar authority; and
(3) take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of such attorney-in-fact, may
be of benefit to, in the best interest of, or legally required by,
the undersigned, it being understood that the documents executed by
such attorney-in-fact on behalf of the undersigned pursuant to this
Power of Attorney shall be in such form and shall contain such
terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees
to indemnify the attorney-in-fact and the Company from and against any demand,
damage, loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorney-in-fact.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in- fact. This Power of Attorney may be filed with the
United States Securities and Exchange Commission as a confirming statement of
the authority granted herein. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an executive
officer of the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 5th day of January, 2022.
/s/ Jason Meyenburg
-------------------
Name: Jason Meyenburg